Treatment Status and Research Progress of Breast Cancer with Low HER2 Expression
-
Published:2024
Issue:09
Volume:14
Page:772-778
-
ISSN:2161-8712
-
Container-title:Advances in Clinical Medicine
-
language:
-
Short-container-title:ACM
Publisher
Hans Publishers
Reference27 articles.
1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers
3. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
4. The Prognostic Significance of Wilms' Tumor Gene 1 in Adult AML with Different Risk Stratification Following Allo-HSCT
5. 熊登宇, 汪贵林, 左怀全. HER-2低表达乳腺癌的临床病理特征及其对新辅助化疗反应[J]. 四川医学, 2022, 43(9): 878-884.